泰格醫藥(03347.HK): 建議採納2022年股票增值權計劃
格隆匯3月29日丨泰格醫藥(03347.HK)宣佈,於2022年3月28日召開的第四屆董事會第二十二次會議上,董事會審議通過採納公司2022年股票增值權計劃。2022年股票增值權計劃將待公司股東於公司股東大會上批准後生效。
根據2022年股票增值權計劃,股票增值權用作激勵工具。據此授予激勵對象的每份股票增值權,在滿足生效條件及生效安排的情況下,可在2022年股票增值權有效期內的行權日獲得公司一股H股增值所得收益(為市價超過行權日行權價的差額)。公司將以現金支付收益。授出股票增值權的上限為不超過44.99萬份股票增值權,佔公吿日期公司股本總額的0.0516%,有效期不超10年。
根據2022年股票增值權計劃,公司於2022年至2025年三個會計年度的業績指標將按年評估,及達成業績指標將視為激勵對象各年度的行權條件。各年度的業績指標如下:

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.